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Abstract Artemisinin-based combination therapies (ACTs)
may influence malaria transmission but the early changes
in parasite populations have not been frequently evaluated.
The changes in Plasmodium falciparum asexual and sexual
populations in the first 16 h following treatment with
artemether-lumefantrine (AL) or artesunate-amodiaquine
(AA) were evaluated in 443 children with acute infections.
The effects of gametocyte density on gametocyte sex ratio
(GSR) were characterized in another cohort of 52 children
treated with AL and AA. Stages of asexual and sexual
parasites in peripheral blood were determined morpholog-
ically. In 167 children there were significant increases in
peripheral asexual parasitemia at 1 h, and in 15 of these,
an insignificant increase in gametocytemia at 1 h, followed
thereafter by a precipitous and significant fall in all patients.
Time-course of GSR showed a female-male-female-biased
cycle at 0 h, 4 h, and 8 h. Pre-treatment GSR and time-course
of GSR post-treatment were independent of density in the
additional cohort of 52 gametocyte carriers treated with AL
or AA. Population changes were similar in AL- and AA-
treated children. Treatment with AL or AA is associated
with early increases in asexual and sexual parasites and is
closely followed by rapid elimination of these parasites.
Keywords P. falciparum; gametocytes; sex ratio; transmis-
sion; ACTs; children
1 Introduction
Artemisinin-based combination therapies (ACTs) are
currently recommended first-line treatments of Plasmodium
falciparum malaria globally because they rapidly reduce
asexual parasite biomass, gametocyte carriage and density,
and subsequently the chances of transmission [47]. In low
transmission settings, for example, in Thailand, ACTs
reduced transmission considerably [23]. However, it is
unclear whether ACTs can reduce transmission in endemic
settings in Africa after consistent use. Although much
is known of the rapid clearance of asexual parasitemia
between 12 h and 24 h after administration of ACTs, little is
known of their effects on the dynamics of asexual parasites
in the hours preceding this period.
The uptake from a human blood meal of viable
Plasmodium falciparum male and female gametocytes
and their subsequent development into gametes in the
mosquito vector are essential to malaria transmission [2,
30]. Mosquito infectivity after a human blood meal, and
subsequent transmission, are dependent on gametocyte
density [18,26,42] and may be perturbed by the gametocyte
sex ratio (GSR) in the blood meal [14,26]. In the latter
context, in experimental studies, Robert et al. [26] showed
that the proportion of infected mosquitoes and the mean
oocyst load increased as sex ratio in the infected human
blood meals increased towards 0.5. Mitri et al. [14] showed
that in cultured gametocytes, at low gametocyte densities,
increasing male sex ratio increases mosquito infectivity
rate and consequently it reduces infectivity rate at high
gametocyte densities. Although much is known of the lethal
effects of artemisinin drugs on young gametocytes [12] and
the reduction in mosquito-infectivity in individuals treated
with ACTs [17], little is known of the effects of ACTs on
the population dynamics of gametocytes and GSR in the
first hours following treatment. Therefore, an understanding
of the dynamics of asexual and sexual parasites in the early
hours following ACTs may assist in identifying the basis of
their effects on transmission.
The present study evaluated the early changes in the
populations of asexual and sexual parasites in the first 16 h
following treatment with ACTs in a group of 443 children
with acute falciparum malaria in an endemic area. The
primary aim was to use the dynamics of asexual and sexual
parasitemias to characterize the basis of the effects of ACTs
on malaria transmission. In addition, the study examined
the effects of ACTs on the interaction between gametocyte
density and sex ratio in another cohort of 52 children with
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Table 1: Treatment regimens and time of study.
Drugs Regimens† No. of patients Year
AL∗ Artemether (20 mg) plus lumefantrine (120 mg) given according to body weight: 5–14 kg
received 1 tablet, 15–24 kg received 2 tablets, 25–34 kg received 3 tablets, > 34 kg
received 4 tablets at presentation, 8 h later and at 24, 36, 48 and 60 h after first dose.
170 2009-10
AAcp∗∗ Artesunate 4 mg/kg daily for 3 d plus amodiaquine 10 mg/kg daily for 3 d (co-packaged)
or according to age: 1-5 years received 1 tablet each of AA,; 6–10 years received 2
tablets each; 11–15 years received 3 tablets each.
193 2009-10
AAcf∗∗∗ Co-formulated amodiaquine plus artesunate given as follows: children weighing ≥ 9–< 18 kg
or aged 1–5 years received 0.5 tablet; children weighing ≥ 18–36 kg or aged 6–13 years
received 1 tablet; children weighing ≥ 36 kg or aged ≥ 14 years received 3 tablets.
72 2009-10
†All drugs were administered orally.
∗AL, artemether-lumefantrine; AAcp, amodiaquine plus artesunate co-packaged; AAcf, amodiaquine plus artesunate co-formulated.
∗∗Each tablet of amodiaquine contains 153 mg base and each tablet of artesunate contains 50 mg.
∗∗∗Each co-formulated tablet contains artesunate 100 mg and amodiaquine base 270 mg.
gametocytemia before and following treatment with ACTs.
The secondary aim was to examine if ACTs modify the
density-dependent impact of sex ratio that may contribute
to mosquito infectivity recently reported in vitro [14].
2 Methods
2.1 Patients
Patients were recruited from April 2009 to March 2010
at the malaria clinic of the University College Hospital in
Ibadan, southwest Nigeria, an endemic area of malaria [28],
into antimalarial efficacy studies of artemether-lumefantrine
(AL) or artesunate-amodiaquine (AA). Patients were
enrolled if their attending relatives gave informed consent;
they were aged 0.5–15 years, had single species asexual P.
falciparum parasitemia ≥ 2,000/μL blood, did not have a
history of significant antimalarial drug intake in the 2 weeks
preceding presentation, and had a good likelihood of being
able to complete 4–6 weeks of follow-up. Patients with
severe malaria [46] or serious underlying diseases (renal,
cardiac or hepatic) or severe malnutrition were excluded
from the study. Additionally, all children who were game-
tocyte carriers before and after treatment with AL or AA
between 2006 and 2009 were included in the study. These
latter children were used to examine the influence of ACTs
on gametocyte density-dependent impact of sex ratio. The
study received approval from the local ethics committee.
2.2 Drug management
At enrolment (day 0) and at follow-up on days 1–7, 14, 21,
28, 35, and 42, patients underwent full physical examina-
tion. Patients were randomized to receive AL or AA (co-
packaged) between April and September 2009 (n = 210),
and to AL or AA (co-packaged) or AA (co-formulated) be-
tween October 2009 and March 2010 (n= 225). Drug treat-
ment was according to standard schedules (Table 1) [37].
2.3 Laboratory investigations
Thin and thick blood films were obtained from a finger prick
for species identification and quantification of asexual and
sexual parasitemia before treatment (0 h), and at 1, 2, 4, 8,
16, 24, 36, 48, and 72 h, and on days 4–7, 14, 21, 28, 35, and
42 after treatment began.
Quantification of asexual and sexual parasites in thick
films was done against 500 and 1000 leukocytes, respec-
tively, assuming a leukocyte count of 6000/μL blood. Stages
of asexual parasite development in peripheral blood were
estimated as follows: R1: width of cytoplasm/diameter of
nucleus ≤ 0.5, that is, ring form aged 0–< 6 h. R2: width of
cytoplasm/diameter of nucleus > 0.5–< 1, that is, ring form
aged 6–< 18 h. R3: width of cytoplasm/diameter of nucleus
> 1, that is, ring form aged 18–24 h. Late trophozoite, that
is, aged > 24–40 h and containing 2 nuclei. Schizonts, that
is, aged > 40 h and containing at least 3 nuclei [13].
All gametocytes were sexed if gametocytemia was
> 10/μL blood and according to the following criteria [2,
26]: males (microgametocytes) are smaller than females
(macrogametocytes), the nucleus is larger in males than
females, the ends of the cells are rounder in males and
angular in females, with Giemsa the cytoplasm stains purple
in males and deep blue in females, and the granules of
malaria pigment are centrally located in females and more
widely scattered in males. Gametocytes were classified
morphologically as male or female if at least three of the five
criteria stated above were present. The sex ratio was defined
as the proportion of gametocytes in peripheral blood that
were male [21,44,45]. GSR was considered male-biased if
sex ratio was > 0.5. Gametocytes were considered immature
or young when they are Stage I–III, or mature when they
are Stage IV–V [31]. Gametocytes were classified as Stage
II if they were enlongated in the erythrocytes or had a
D-shape and distinguished from late trophozoites with 2
nuclei. Blood obtained from a finger prick into heparinized
capillary tubes was used to estimate hematocrit.
Since there were rapid increases followed by rapid
decreases in asexual and sexual parasite populations, the
areas inscribed by the increases and decreases roughly
represented triangles. The area was calculated as half the
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Table 2: Characteristics of 435 children enrolled in the study.
Variable AA (273) AL (170) ALL (443) P value
Male:female 136:137 89:81 225:210 .67
Age (year) 7.1±0.2 [1–15]∗ 6.7±0.2 [1–13] 7.0±0.1 [1–15] .18
< 5 years 59 51 110 .06
Duration of illness (d) 2.6±0.1 [1–7] 2.8±0.1 [1–10] 2.7±0.1 [1–10] .18
Weight (kg) 19.6±0.4 [6–46] 18.8±0.5 [6–36] 19.3±0.32 [6–46] .23
Temperature °C 38.4±0.1 [36–41] 38.5±0.1 [36–41.1] 38.4±0.1 [36–41.1] .56
> 40 °C 22 15 37 .91
Hematocrit (%) 32.3±0.3 [17–45] 32.1±0.4 [17–40] 32.2±0.2 [17–45] .61
< 30% 51 34 83 .82
Number with hepatomegaly 62 61 123 .003
Number with splenomegaly 36 22 58 .94
GMPD (/µL of blood) 64546 78397 70129 .053
Range 2791–1125000 2837–1105263 2837–1125000
GMGD (/µL of blood) 48 88 55 .06
Range 6–168 72–108 6–168
∗Values are given as mean ± sem [range], GMPD geometric mean parasite density, GMGD geometric mean gametocyte density.
AA, amodiaquine-artesunate; AL, artemether-lumefantrine.
time interval between the increases and decreases, that is,
half the base of the triangle multiplied by the height, that
is, the numerical increase in asexual or sexual parasites
from baseline. These areas were assumed, theoretically,
to represent the biomass of the parasites mobilized and
eliminated from the body.
2.4 Data analysis
Data were analyzed using version 6 of the Epi-Info soft-
ware [4] and the statistical programme SPSS for Windows
version 10.01 [41]. Variables considered in the analysis were
related to the densities of P. falciparum gametocytes and
trophozoites. Proportions were compared by calculating χ2
with Yates’ correction or by Fisher exact test. Normally dis-
tributed, continuous data were compared by Student’s t-test,
and analysis of variance (ANOVA). Data not conforming to
a normal distribution were compared by the Mann-Whitney
U-tests or the Kruskal-Wallis tests or by Wilcoxon ranked
sum test. All tests of significance were two-tailed. P -values
of < 0.05 were taken to indicate significant differences. Data
were (double)-entered serially using the patients’ codes and
were only analyzed at the end of the study.
3 Results
3.1 Characteristics of patients enrolled in the study
The characteristics of patients enrolled in the study are
summarized in Table 2. One hundred and ten children were
aged < 5 years. Geometric mean asexual parasitemia was
70,129/μL, 95% CI 60,072–79,231.
3.2 Changes in asexual parasitemia during first hours fol-
lowing treatment
Overall, there was an increase in asexual parasitemia in 167
of 443 children (62 of 170 treated with AL and 105 of 273
treated with AA, P = .74) during the first 2 h after treatment
commenced. Figure 1(a) shows the changes in asexual
parasite density in the first 8 h following treatment with
ACTs. In the 167 children, there were significant increases
in asexual parasitemia at 1 h after commencing treatment
compared with pre-treatment (74,291 v 60,101/μL,
P < .001) and was immediately followed by a precipitous
and significant fall in parasitemia at 8 h onward. Enrolment
characteristics of those with increase or no increase in
asexual parasitemia at 1 h were similar: age 7.1 ± 0.2 v
6.7 ± 0.2 years, P = .12; body temperature 38.4 ± 0.1 v
38.5±0.1 °C, P = .48; hematocrit 32.6±0.3 v 32.6±0.5%,
P = .91. However, enrolment asexual parasitemia was
significantly lower in those with increase compared with
those without increase 60,101 (range 2,657–1,125,000) v
81,429 (range 2,837–1,105,263)/μL, P = .003. In addition,
patients with no increase in asexual parasitemia had no
gametocytemia at enrolment.
Figure 1(a1) shows that increases and decreases in those
treated with AL and AA between 1 and 2 h roughly represent
a triangle. The areas inscribed by the triangles were similar
for the two drugs (47,663 v 50,853 af (asexual forms)/μL.h,
P = .28).
3.3 Changes in gametocyte density during first hours fol-
lowing treatment
Gametocytemia was present at enrolment in 17 of 443
children and in 2 children by the end of one week after
treatment began. The difference in the proportions was
significant (χ2 = 10.5, P = .001). Overall, gametocytemia
increased in 14 of 17 gametocyte carriers at 1 h and peaked
at 4 h, but there was no significant increase in density
(P = .18) (see Figure 1(b)). Fifteen of 17 gametocyte
carriers also had associated increase in asexual parasitemia
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Figure 1: Variations in asexual parasite density (a), gametocyte density (b) and gametocyte sex ratio in the first 16 h following
treatment with artemether-lumefantrine (AL) or artesunate amodiaquine (AA). Error bars indicate standard error of mean.
at 1 h. Peak increase in gametocyte density occurred at 2 h
and 4 h in patients treated with AA and AL, respectively,
and represented two triangles with similar areas: (62.3 v
112.7 sf (sexual forms)/μL.h, P = .57 (see Figure 1(b)). In
the two children who had gametocytemia at the end of one
week, gametocytes were no longer detected in peripheral
blood at the end of two weeks.
3.4 Changes in gametocyte sex ratio during the first hours
following treatment
Figure 1(c) shows the variation in gametocyte sex ratio in
these children. Overall, there was a female-male-female-
biased cycle at 0 h, 4 h, and 8 h, (n = 17, 10, 3, resp.),
respectively. The sex ratio at 4 h was not significantly higher
than at 0 h (weighted mean 0.39 v 0.33, P = .44) but the
sex ratio at 8 h was significantly lower than at 0 h (weighted
mean 0.21 v 0.39, P = .047).
3.5 Stages of gametocytes found in peripheral blood during
the first hours following treatment
Mature male and female gametocytes were mainly found in
peripheral blood in those with gametocytemia (Figure 2).
However in 7 children, who had no young gametocytes in
their pre-treatment blood slides, young gametocytes were
also present in a very small number within 8 h of initiating
treatment (Figure 2). In these children, young gametocytes
were not found after 16 h.
3.6 Relationship between gametocyte density and gameto-
cyte sex ratio during the first hours
Figure 3 shows that there was no significant relationship
between parasite density and sex ratio at enrolment (r =
0.08, P = .9, n = 17, 13, 14, 10, and 3 at 0, 1, 2, 4, and
8 h, resp.).
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Figure 2: Light micrograph of P. falciparum; (a)-(b) mature male gametocytes, (c)-(d) mature female gametocytes, (e)-
(f) young gametocytes following treatment with artemether-lumefantrine (AL) or artesunate amodiaquine (AA). Note the
D-shaped appearance suggesting stage IIb and oat grain appearance suggesting stage IIa.
Figure 3: Relationship between gametocyte density and
gametocyte sex ratio in the first 8 h following treatment with
artemether-lumefantrine and artesunate-amodiaquine. Data
for both drug combinations have been combined.
3.7 Stages of asexual parasites in peripheral blood during
the first hours following treatment
Table 3 summarizes the stages of parasites in peripheral
blood in 40 randomly selected children, who had increase
(20 children) or no increase (20 children) in asexual
parasitemia in the first 4 h of treatment. In each group,
the proportion of each stage is similar at 0 h and at 2–4 h.
However, in patients with increase in asexual parasitemia in
the first 2 h, the proportion of ring-shaped asexual parasites
18–24 h old increased significantly at 2–4 h after treatment
(P = .02). Schizonts were found in peripheral blood of 1
child at 0 h and in 4 children at 2–4 h (Figure 4).
3.8 Effects of ACTs on relationship between density and sex
ratio in children before and after treatment
In order to examine more carefully the relationship between
gametocyte density and sex ratio, an evaluation of all
patients treated with AL or AA between 2006 and 2009 was
carried out. There were 52 children who carried gametocytes
in the first 8 days.
Figure 5(a) shows the distribution of gametocyte densi-
ties and sex ratios at enrolment in 52 gametocyte carriers.
Sex ratio did not alter significantly with gametocyte density:
the proportion of patients with a male-biased sex ratio was
10/22 (45%) and 12/30 (40%) when gametocyte densities
were < 20/μL and ≥ 20μL, respectively (χ2 = 0.012, P =
.91). The weighted mean sex ratios were similar at enrol-
ment in those with low and high gametocyte densities (0.43
v 0.35, P = .28). Prior to treatment with AL or AA, there
was no significant correlation between gametocyte density
and sex ratio (r =−0.14, P = .29) (Figure 5(b)).
Figure 6 shows the temporal changes in GSR in children
with low or high gametocytemia. Irrespective of density,
6 Malaria Chemotherapy, Control & Elimination
Table 3: Stages of asexual parasites in the periphery during the first hours following treatment.
Increase in asexual parasitemia No increase in asexual parasitemia
(n= 20) (n= 20)
Stages of parasite Before After† P value Before After† P value
Very young rings (0–< 6 h) [R1] 0‡ 0‡ — 0‡ 0‡ —
Young rings (6–< 18 h) [R2] 9 1 0.8 2 3 1.0
Mature rings (18–24 h) [R3] 10 18 0.02 15 14 1.00
Late trophozoites (24–40 h)∗ 0 1 0.5 3 3 0.7
Schizonts (> 40 h)∗∗ 1 4 0.3 0 0 —
†2–4 h after oral ACTs.
‡Indicate number of patients.
∗Containing 2 nuclei.
∗∗Containing at least 3 nuclei.
Figure 4: Schizonts obtained from two patients, note the
ring form in the background.
GSR was female-biased during follow-up. There was no
difference in sex ratio values at all times during follow-up in
children with low or high gametocyte density. For example,
on day 3, mean sex ratio values were 0.40 (n= 6) and 0.13
(n= 12) in patients with low and high gametocyte densities,
respectively.
4 Discussion
The study showed increases in asexual and sexual para-
sitemia in approximately 40% of patients in the first few
hours of initiating treatment with AL or AA. Virtually
all of gametocyte carriers who had increases in their
gametocytemias also had increases in their asexual
parasitemias suggesting a common mode(s) for increases in
asexual and sexual parasitemias. Increase was significant for
mature rings 18–24 h old. The increases were followed by
a rapid decline in parasitemias. This process and sequence,
taken together, may be beneficial in a number of ways: they
may reduce the subsequent sequestered mass and limit the
deleterious consequences of sequestration and/or facilitate
removal, by pitting, of parasites from the red cells by the
spleen. Thus, increases (the hypothetical mobilization)
may be effects of ACTs during early hours of treatment
and may contribute to their parasitological actions. The
latter is supported by ex vivo parasite viability studies that
showed that the viability of circulating asexual parasites
is significantly reduced by artemisinin drugs about 6–12 h
after start of treatment compared to quinine or sulfadoxine-
pyrimethamine [15,40]. An alternative explanation for the
(a)
(b)
Figure 5: (a) Distribution of gametocyte densities and
sex ratios at enrolment in a cohort of 52 children before
treatment with artemether-lumefantrine or artesunate-
amodiaquine. Data for both drug combinations have been
combined. (b) Relationship between gametocyte density
and sex ratio at enrolment in a cohort of 52 children
before treatment with artemether-lumefantrine or artesunate
amodiaquine. Data for both drug combinations have been
combined.
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Figure 6: Time-course of sex ratio in 52 gametocyte carriers
with high or low gametocytemia following treatment with
artemether-lumefantrine or artesunate-amodiaquine.
increases in the number of late stage asexual parasites found
in peripheral blood is the asynchrony of the infections
and the differences in time interval between release of
merozoites and the time of presentation.
Gametocyte carriage in the children, on presentation,
was very low (3.8%) and, compared with carriage in
the years preceding 2009, showed a significant decline:
gametocyte carriage on presentation was 21.6% (21/97)
in 2002, 22.7% (41/181) in 2004, 13% (51/391) in
2005, 12% (42/350) in 2007–2008, and 2% (9/435) in
2009 [34,35,36,39]. However, these rates are likely to be
underestimates because of significant submicroscopical
gametocytemia detectable by polymerase chain reaction
(PCR) in children from this and other endemic areas [10,
18,29] that may substantially contribute to the already large
gametocyte reservoir and mosquito infectivity even after
ACTs [18] or primaquine. Additionally, an efficient vector,
Anopheles gambiae, and environmental conditions permit
easy transmission. Thus, in this endemic area, despite
significant decreases in gametocyte carriage in children
with acute malaria after 5 years of adoption of ACTs as
first-line treatments, asexual parasite rate of 37%, a measure
of transmission intensity, is little affected [6].
Late trophozoites, schizonts, and young gametocytes
of P. falciparum are scarcely found in peripheral blood of
African children [32]; young gametocytes are sequestered in
bone marrow and spleen [5,32,43]. In the present cohort of
children, schizonts and stage IIb gametocytes were found in
peripheral blood within 8 h of initiating treatment and they
disappeared within 16 h in 11 (2.5%) of the children. If the
presence, in peripheral blood, of young gametocytes, can be
confirmed during the early hours of initiating ACTs and their
disappearance after 24 h of treatment, by immunoassay or
reverse transcription-PCR, this would suggest mobilization
from sequestered sites by ACTs. Following ACTs use, 60–
90% of all gametocytes would have emerged by 24 h [22,
39]. Therefore, as insensitivity develops to ACTs in this
endemic area, and as has been shown in areas of Southeast
Asia where insensitivity has now developed to ACTs,
gametocyte carriage would increase [1].
Overall, as expected, GSR was female-biased on
enrolment and remained so following treatment until
gametocytemia was no longer detectable after 3 days of
initiating treatment. However, there was no significant
correlation between gametocyte density and sex ratio before
and after four hours following initiation of treatment and
even in the additional cohort of 52 children. A correlation
between density and gametocyte sex ratio has been reported
in children treated with non-artemisinin drugs from this
endemic area [34]. If low gametocytemia is associated with
increasing sex ratio, a negative correlation would have been
expected. Thus, it is probable that AL or AA may influence
the parasite’s mechanism of facultatively adjusting their sex
allocation in response to low gametocytemia. Alternatively,
they may have little or no effects and the observations in the
present study may reflect a natural phenomenon.
In this endemic area, falciparum infections in children
are multi-clonal [9,8,11,38] and in accordance with
evolutionary theory that predicts that sex ratio becomes less
female-biased as clone number increases due to competition
among clones for mating success—local mate competition
(LMC) [7,16,25], increasing clone number is associated
with less female-biased sex ratio in naturally infected
children [38]. However, rapid elimination of asexual
parasites by AL or AA may, presumably, significantly
reduce the number of circulating clones and produce a
less male-biased sex ratio (MBSR) when the remaining
viable committed asexual parasites eventually develop to
gametocytes. This effect should become apparent after
one week of ACTs, since development from asexual to
sexual parasites takes approximately 10 days [30]. This
is consistent with a recent finding from this endemic area
showing that by the end of 7–14 days, GSR in children
treated with artesunate or artesunate-amodiaquine became
female-biased irrespective of pre-treatment GSR [35].
Parasites are also thought to alter their sex allocation to
ensure successful fertilization by producing enough males
to fertilize its females particularly when gametocyte density
is low and gametocyte viability compromised, for exam-
ple, from host immune response—the so-called fertilization
insurance [45] and as the infection progresses and anaemia
develops [19,20,27]. ACTs may not worsen the anaemia
of malaria infection [3,33,37] and therefore less likely to
promote the male-biased sex ratio associated with anaemia.
In order to quantify the increases in parasites in
peripheral blood over time, the concept of area of triangle
resulting from the sharp increase and rapid decline of
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parasitemias was used. These triangles showed that
increases in asexual and sexual parasites overlapped,
but the sex ratio triangle occurred later. The reasons for
the lag are unclear. The time-course and areas of the
triangles for asexual and sexual parasites for AL- and AA-
treated children were not similar suggesting that artesunate
in AA may cause relatively early increases compared
with artemether in AL. These differences, however, did
not translate to a significant difference in asexual and
gametocyte clearance in patients treated with AA and AL.
Based on the findings in the first few hours following
administration of AL or AA to individuals with acute
falciparum malaria, and on the time-course of GSR in
the one week following initiation of treatment, it would
appear that a rapid elimination of large parasite biomass
involving both committed and non-committed parasites
prevented these parasites from progressing to development
into gametocytes and averting changes in GSR that may
favor increased mosquito infectivity.
There are limitations of the present study. Although
gametocyte densities and sex ratio changes were evaluated
and used to surmise the effects of ACTs on transmission,
there is a need to consider gametocyte viability in order
to reveal the full impact of ACTs on transmission.
Additionally, gametocytes sex ratio data were derived
from few patients necessitating caution with extrapolation.
The assumption that the hypothetically mobilized parasites
were actually all eliminated cannot be proven completely.
It is possible that some of the parasites may escape killing
effects of ACTs. Overall, the sequestered parasite biomass
is unknown in any of the patients making it difficult to
estimate the fraction of the sequestered biomass that were
hypothetically mobilized. The contribution of immunity to
the observed changes could not be evaluated. Finally AL or
AA concentrations were not measured making it difficult
to examine the relationship between the drug effects and
drug concentrations during the critical early stage of drug
administration.
Currently, primaquine, the gametocytocidal 8-amino-
quinoline, when combined with artemisinin drugs is
thought to accelerate gametocyte clearance in infected
patients [24]. However, the effects of these combinations
or of primaquine alone on the early changes in sexual
populations during the first few hours of initiating treatment
are unknown. Additionally, the effects of primaquine alone
or in combination with artemisinin drugs on gametocyte sex
ratios in the first few hours after treatment are also unknown.
It is essential that these change if any be evaluated.
In conclusion, treatment with AL or AA is associated
with early increases in peripheral asexual or sexual parasites
during the first 8 h of initiating of therapy in 40% of children,
and is followed by early, rapid elimination of large parasite
biomass that may contribute to reduction in transmission.
Nomenclature
ACT: Artemisinin combination therapy
GSR: Gametocyte sex ratio
AA: Artesunate-amodiaquine
AL: Artemether-lumefantrine
ANOVA: Analysis of variance
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